Ichnos Sciences in licence deal with Almirall
Ichnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Ichnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders.
Biologicals and vaccine specialist CSL Ltd is set to acquire Swiss Vifor Pharma Ltd for CHF10.9bn.
German Apogenix AG has received a 26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.
The 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners).
US cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received 32m in funding by Enterprise Greece.
The European Commission has inked the pre-purchase agreement over Valnevas inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.
Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.
Life Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.
Dunad Therapeutics Ltd had entered into a $1.3bn option deal with Swiss pharma major Novartis AG to develop targeted protein degrader therapies.
Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.